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http://dx.doi.org/10.1016/j.pedneo.2Background: Selenium is an essential trace element and as a component of selenoproteins it
plays a key role as an antioxidant. We aimed to evaluate the effect of selenium supplementa-
tion during pregnancy on cord blood selenium content and lipid profile.
Methods: This trial was performed on 166 eligible women who were randomized to receive
100 mg of selenium, as selenium-yeast (Se group) or a placebo-yeast tablet (placebo group).
Umbilical cord blood samples were collected at the time of delivery and selenium concentra-
tion and lipid profile were measured.
Results: Triglyceride levels were found to be significantly higher in the Se group than in the
placebo group (pZ 0.01). However, no significant difference in cord blood selenium was
observed between the groups nor were there any significant correlations between cord blood
selenium and lipid profile parameters.y of Nutrition Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mash-
ac.ir (M. Ghayour-Mobarhan).
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Selenium supplementation and cord blood lipid profile 335Conclusion: Our findings suggest that selenium supplementation in pregnant women may be
associated with an increased cord-blood triglyceride level, although total cholesterol,
low-density lipoprotein and high-density lipoprotein cholesterol levels did not change signifi-
cantly. The clinical significance of the increased cord triglyceride concentration needs to be
evaluated.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Selenium is an essential trace element and a key component
of important enzymes, including the antioxidant glutathione
peroxidase and the iodothyronine deiodinases.1 A number of
selenoenzymes play key roles in protecting against oxidative
damage.2 The mammalian fetus is sensitive to reactive
oxygen species (ROS) during development. Fetal cell growth
in vitro has been shown to be impaired in a dose-dependent
manner in the presence of ROS.3 Antioxidant vitamin treat-
ment increases the number of zygotes and improves the
transformation of zygotes to blastocytes in vitro.4 Micro-
nutrient deficiency during pregnancymay lead to growth and
developmental delay of fetal organs and may adversely
affect immune function.5 Antioxidant defenses are depen-
dent on micronutrient status; the immune system is
compromised in malnourished pregnant women and their
neonates are small for gestational age (SGA).6 One effective
strategy for preventing the development of oxidative stress
in the newborn may be by enhancing maternal antioxidant
status via supplementation with nutrients such as selenium.7
In the current study, we sought to investigate the effect of
selenium supplementation during pregnancy on umbilical
cord selenium content and on cord blood-lipid profile.2. Methods
Two hundred and eighteen pregnant women age 16-35 years
were assessed for eligibility to participate in this randomized
double-blind placebo-controlled trial. Study participants
were selected from women referred to the Obstetrics and
Gynecology Department of Ghaem Hospital (Mashhad, Iran)
between June 2007 and June 2009. Inclusion criteria for
selection were gestational age up to 12 weeks and no indi-
cations for terminating the pregnancy. Exclusion criteria
included the use of any drugs except routine supplements of
folic acid and ferrous sulfate and a history or clinical features
of any medical conditions including thyroid disorders, dia-
betes, hypertension, hyperlipidemia, and infections. The
Ethics Committee of the Mashhad University of Medical
Science (MUMS) approved this study and all individuals signed
informed consent. In this trial, eligible individuals were
randomly assigned to receive 100 mg of selenium as a sele-
nium-enriched yeast tablet (Se group) or a placebo-yeast
tablet (placebo group) daily for the last 6 months of preg-
nancy. Individuals were alternatively allocated to tablets
coded A or B, with the first code chosen randomly. The dose
of selenium used was in agreement with the National
Academy of Sciences’ guidelines that established a safeupper limit of 400 mg/day for selenium intake.8 Both the
placebo and the selenium-enriched yeast tablets were
provided by Pharma Nord (Vejle, Denmark). Maternal groups
were similar for parameters such as anthropometric indices
(weight, length, body mass index), socioeconomic status
(education and career), medical history (infertility and
miscarriage), complete blood count, and blood typing. Study
physicians, research nurses, and participants were unaware
of the assignment groups (tablets were administered as A or
B). Before administration of the tablets, the participants
were asked to sign a written consent form and complete
a questionnaire providing details of age, weight, height,
blood pressure, date of last menstrual period, contraceptive
methods, smoking habit, alcohol use, and consumption of
routine supplements during pregnancy. On delivery, umbil-
ical cord blood was collected. Serum selenium concentration
and lipid profile were measured in these samples.
Twohundred andeighteenpregnantwomenwere assessed
for eligibility to participate in this trial. Thirty-nine individ-
uals did not meet the inclusion criteria and were excluded
from the study. Of the 179 individuals who entered the trial,
13 dropped out because of intolerance to the tablets (nZ 4)
or the unpleasant aroma associated with them (nZ 9). One
hundred twenty-five individuals completed the study (61 in
the Se group and 64 in the placebo group, Figure 1). Because
some of the women did not eventually deliver their babies in
our hospitals; we were only able to collect umbilical cord-
blood samples from 34 and 32 participants in the Se and
placebo groups, respectively. Samples were analyzed in
a single laboratory. Blood was centrifuged at 2500 rpm for 15
minutes at room temperature to obtain serum. Serum lipid
profile parameters including total cholesterol, low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), and triglycerides were measured by
routine enzymatic methods using commercial kits. Serum
selenium was determined by electrothermal atomic absorp-
tion spectrometry with Zeeman background correction using
a palladium chloride chemical modifier.
All statistical analyses were performed using SPSS 11.5,
Chicago, IL. Values were expressed as mean standard
deviation. The group comparisons were assessed by the
Student t-test or the Mann-Whitney U test. Pearson and
Spearman correlation tests were performed for normally
and non-normally distributed data. A two-tailed p< 0.05
was considered statistically significant.
3. Results
Basic and clinical findings including sex, gestational age,
birth weight, birth length, birth head circumference, and
Participated in study (n = 179) 
Thirteen subjects were excluded 
after the first consumption of tablet 
because of intolerance to tablet.   
Randomized
(n = 166)  
Selenium yeast (100 µg/d) 
(n = 83) 
Placebo yeast
(n = 83) 
Collected cord samples  
(n = 32) 
Collected cord samples  
(n = 34)
Excluded
(n = 39) 
Completed
(n = 61) 
Completed
(n = 64) 
Withdrawals from treatment
(n = 22) 
Withdrawals from treatment
(n = 19) 
Assessed for eligibility
(n = 218)
Figure 1 Flowchart of patient allocation in the study.
336 H. Boskabadi et alApgar scores at first and fifth minutes did not show any
significant difference between neonates in the Se and
placebo groups (p> 0.05) (Table 1). The umbilical cord
serum- selenium concentration was comparable in Se andTable 1 Basic and clinical findings of study neonates.*
Parameter Se group Placebo group p-value
Gestational
age (wk)
39.0
(39.0e40.0)
39.0
(38.0e40.0)
>0.05
Sex (% female) 44.2 41.8 >0.05
Weight (g) 3085.3 622.2 3069.0 551.1 >0.05
Length (cm) 50.0
(49.0e51.0)
50.0
(48.0e51.0)
>0.05
Head
circumference (cm)
34.4 1.4 34.5 2.9 >0.05
Apgar score
(first min)
9.0 (8.0e9.0) 9.0 (8.0e9.0) >0.05
Apgar score
(fifth min)
9.0 (9.0e9.0) 9.0 (9.0e9.0) >0.05
* Values are expressed as percentage, mean standard devi-
ation or median (interquartile range).placebo groups (p> 0.05, Table 2). Maternal serum selenium
concentrations increased in the Se group by the end of the
trial (122.5 23.2 mg/L at baseline and 168.6 36.4 mg/L
posttrial; p< 0.001) whereas no significant change wasTable 2 Comparison of cord serum selenium and lipid
profile in selenium and placebo group.*
Parameter Group p-value
Selenium
group (n Z 32)
Placebo
group (n Z 34)
Selenium (mg/L) 106.3 18.2 101.9 15.9 0.29
Total cholesterol
(mg/dL)
96.7 55.7 79.6 39.9 0.16
Triglyceride
(mg/dL)
56.0
(41.0e105.0)
38.5
(32.7e67.0)
0.01
LDL-C (mg/dL) 58.0 39.6 45.1 27.2 0.13
HDL-C (mg/dL) 23.0 8.5 20.2 8.1 0.17
HDL-CZ high-density lipoprotein cholesterol; LDL-CZ low-
density lipoprotein cholesterol.
* Values express as mean standard deviation for normally
distributed data and median interquartile range for non-
normally distributed data.
Selenium supplementation and cord blood lipid profile 337observed in the placebo group (122.9 26.9 mg/L at baseline
and 119.4 33.4 mg/L posttrial; p> 0.05). There was no
significant difference in total cholesterol, LDL-C, and HDL-C
in cord blood serum between Se and placebo groups
(p> 0.05), whereas the triglyceride level was significantly
higher in the Se group (pZ 0.01, Table 2).With respect to the
bivariate correlations, we did not find a significant correla-
tion between cord-serum selenium and the lipid profile
parameters of total cholesterol, triglycerides, LDL-C, and
HDL-C (p> 0.05; Table 3).4. Discussion
Pregnancy is often regarded as a condition of oxidative
stress. Several factors are responsible for this type of
stress, including increased oxygen intake and consumption,
high metabolic demand, and labor-associated stress.9
Previous reports have confirmed elevated levels of lipid
peroxides and reduced antioxidant enzyme activities in the
blood circulation of pregnant women. In addition, the
placenta is a major source of lipid peroxides and oxidative
stress. This increased lipid peroxidation along with the
exposure to high oxygen concentration at birth, inflamma-
tion, and an immature antioxidant defense system make
the neonates, especially those who are preterm, suscep-
tible to oxidative stress.10 Oxidative stress has been sug-
gested to be implicated in the pathophysiology of multiple
pregnancy complications such as preterm premature
rupture of membranes, bronchopulmonary dysplasia,
intrauterine growth restriction, persistent ductus arterio-
sus, intracranial hemorrhage, and fetal death.11
As selenoproteins might be expected to have a protec-
tive effect against oxidative damage to lipoproteins such as
LDL, supplementation with selenium may have a beneficial
effect during pregnancy. However, clinical trials investi-
gating the effect of prenatal selenium supplementation on
cord blood lipid profile are lacking. In observational studies,
serum selenium concentrations have been reported to be
positively and significantly correlated with serum choles-
terol. This correlation was found to remain significant after
adjustment for age and body mass index.12 Lipoproteins,
apolipoproteins, and in particular triglycerides increase
significantly in maternal serum during pregnancy, which
may be due to hormonal changes and increased hepatic
lipase activity.13
The results of our trial indicated that selenium supple-
mentation is associated with an increase in serum triglyc-
eride concentration in cord blood (56.0 vs. 38.5 mg/dL,Table 3 Correlation of cord serum selenium level with compon
Parameter Se group
R p r
Total
cholesterol
0.16sp 0.37 
Triglyceride 0.09sp 0.60 
LDL-C 0.37sp 0.13 
HDL-C 0.24 0.18 
HDL-CZ high-density lipoprotein cholesterol; LDL-CZ low-density lippZ 0.01). However, total cholesterol, LDL-C, and HDL-C did
not change significantly post-trial. Therefore, although the
clinical effect of increased cord triglycerides remains to be
evaluated, daily administration of 100 mg selenium to preg-
nant women during the second and third trimesters does not
seem to be associated with a negative effect on the
newborn’s total cholesterol, LDL-C, and HDL-C values.
Several previous observational studies have reported
a positive association between serum selenium concentra-
tions and lipid levels.14 However, the findings of interven-
tion studies have been less clear. Selenium deficiency has
been reported to be linked with reduced lipid levels.15 With
regard to clinical studies, there have been three reports on
the effect of selenium supplementation on plasma lip-
ids.16e18 Findings of trials by Luoma et al.16 and Yu et al.17
did not show any significant effect of selenium on plasma
lipids. However, a recently published robust trial by Ray-
man et al.18 showed modest reductions in total and
nonehigh-density lipoprotein cholesterol levels on supple-
menting either 100 mg/day or 200 mg/day of high-selenium
yeast. However, at a higher dose (300 mg/day), no signifi-
cant effect was observed on total or nonehigh-density
lipoprotein cholesterol levels although HDL-C was signifi-
cantly increased.
The mean baseline selenium concentration in maternal
serum of both selenium and placebo groups was reported to
be higher than the mean selenium concentration in non-
pregnant women in other countries, including India, Spain,
Poland, Norway, Estonia, and the Netherlands.19e24
Furthermore, the levels found in the current study were
also higher than those reported in non-pregnantwomen from
other parts of Iran.25,26 The difference in selenium status is
probably due to the regional and geographic variability in the
selenium content of soil and plant foods.27,28 Selenium
administration in pregnant women did not increase the cord
blood-serum selenium significantly. The cord blood serum
selenium in our study was lower than that of maternal serum
selenium, which is consistent with most previous reports,
such as the study of Gathwala et al.29 that reported the cord-
blood serum selenium as 54.17 13.4 mg/kg (ppb). In
comparison with the normal range (50e150 ppb), this re-
ported cord blood-selenium concentration may be consid-
ered as a low normal value. Makhoul et al.30 reported cord
blood serum selenium to be 60e70% that of maternal serum
selenium. A possible explanation for the observed low cord
blood-serum selenium levels might be the uptake of seleno-
protein P via apoE R2 receptor in the placental tissue. Sele-
noprotein P is synthesized and secreted by the liver and
comprises most of the plasma selenium content.31 Uptake ofents of lipid profile in cord blood serum.
Placebo group Total
p r p
0.20sp 0.27 0.01sp 0.95
0.10sp 0.60 0.04sp 0.76
0.17sp 0.35 0.08sp 0.51
0.52 0.77 0.13 0.30
oprotein cholesterol; spZ Spearman correlation coefficient.
338 H. Boskabadi et alselenium by apoE R2 (a member of the lipoprotein receptor
family) has been shown previously in the testis and the
brain.32 Lower levels of cord blood selenium compared with
maternal seleniumconcentrationsmight be attributed to the
high metabolic demands of the fetus or the action of
metallothionein-1. Metallothionein-1 is a metal-binding
protein in the human placenta that sequesters some metals
and can influence the distribution of selenium between
serum and tissues.30 However, the exact mechanism for the
selenium gradient between maternal and neonatal serum is
not yet clear.8 Indeed, some factors such as age, dietary
regimen, physical activity, and disease may affect serum
seleniumconcentration. Another important factor that could
affect the serum selenium level is the acute phase/inflam-
matory response. Previous studies have shown a negative
association between plasma selenium concentrations and
selenoprotein expression with inflammation.33,34 Therefore,
measurement of inflammatory markers would help give
amore reliable interpretation of selenium status in different
conditions. The results of our trial may have been influenced
by the level of selenium intake in our soils and foods, which
led to a relatively high selenium concentration in partici-
pating women. In addition, larger multicenter trials, pref-
erably with different doses of selenium and in regions of
different selenium status, would be helpful to confirm the
efficacy of prenatal selenium supplementation on cord blood
lipid profile.5. Conclusion
Selenium supplementation in Iranian pregnant women may
increase triglycerides levels in cord blood, although noeffect
was found on total cholesterol, LDL, and HDL levels. The
advantages and disadvantages of high levels of serum
triglycerides in infants need to be evaluated. Most fatty acids
in human milk are in the form of triglycerides, and lipids
represent approximately 50%of the calories in humanmilk. It
must be noted that the relatively small number of partici-
pants (completers) who were evaluated in the current study
may have affected the interpretation of our results. There-
fore, the current findings need to be confirmed by future
large-scale trials with better characterization of maternal
selenium and glucose tolerance status.Acknowledgments
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